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A simple, accurate, precise and robust stability indicating RP-HPLC assay method has been 
developed for the estimation of trimethobenzamide in stress sample. An isocratic separation of 
trimethobenzamide was achieved on Kromasil 100 C-18 column (250 X 4.6mm, 5μ) with a flow rate 
of 1.0 ml/min and by using a photodiode array detector to detect the analyte at 213nm. The optimized 
mobile phase consisted of methanol: ammonium formate (44:56, v/v). The drug was subjected to 
different forced degradation conditions according to ICH guidelines including acid, base, neutral 
hydrolysis, oxidation, photolysis and thermal degradation. Degradation products were found only 
in basic and oxidative degradation conditions. All the degradation products got eluted in an overall 
analytical run time of 12min. The developed analytical method has been validated according to the 
ICH guidelines. Response of trimethobenzamide was linear over the concentration range of 0.5-50μg/
mL (r2 = 0.999). Accuracy was found to be in between 94.03% to 100.39%. Degradation products 
resulting from the stress studies did not interfere with the detection of the analyte.
Keywords: Trimethobenzamide. Stability indicating assay method. Method development and 
validation. RP-HPLC.
INTRODUCTION
Trimethobenzamide hydrochloride chemically 
N-[p-[2-(dimethylamino) ethoxy] benzyl]-3, 4, 
5-trimethoxybenzamide monohydrochloride is a potent 
antiemetic molecule used to treat nausea and vomiting. It 
is prescribed to patients with gastroenteritis, medication-
induced nausea and another type of similar conditions. 
Trimethobenzamide is an antagonist of the dopamine D
2
 
receptor. It exerts its effect on the chemoreceptor trigger 
zone of the medulla oblongata to suppress nausea and 
vomiting (DeCamp et al., 2008; Smith, Cox, Smith, 
2012). It is marketed under the trade name Tebamide and 
Tigan, by King Pharmaceuticals and GlaxoSmithKline 
in the formulation of oral capsules and parenterals 
(Gregory et al., 2004). 
Forced degradation study is helpful for the 
development of stability indicating method, determination 
of intrinsic stability of drug molecule, establish the 
recommended storage conditions and finally establish the 
quality, safety and efficacy of the drug substance and drug 
product (Baertschi, 2011; Blessy et al., 2014; Gregory et 
al., 2004; Singh et al., 2013). Literature survey reveals 
that till date, there is no stability indicating assay method 
exist for quantitation of trimethobenzamide in presence of 
their degradation products. In this study, a simple robust 
and sensitive reverse phase-high performance liquid 
chromatography (RP-HPLC) method has been developed 
for the quantitative determination of trimethobenzamide 
in forced degradation sample. Forced degradation studies 
are carried out according to ICH Q1 R2 guidelines 
under different stress conditions like acid, base, neutral 
hydrolysis, oxidative, thermal and photodegradation 
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(ICH, 2005; Ngwa, 2010; Reynolds et al., 2002; Singh, 
Rehman, 2012). The developed analytical method was 
validated following the same ICH Q1 R2guideline 




Pure trimethobenzamide hydrochloride (>98%) 
was procured from Sterling Biological Limited 
(Ahmedabad). Hydrochloric acid AR grade (HCl) and 
sodium hydroxide AR grade (NaOH) were obtained 





was purchased from Qauligens. Acetic acid AR grade 
was purchased from Fisher Scientific, India and 
S.D. Fine Chemicals Ltd. Ammonium acetate and 
ammonium formate were obtained from S.D. Fine 
Chemicals Ltd and Merck India Pvt Ltd., respectively. 
HPLC grade methanol (MeOH) was purchased from 
Fischer Scientific. HPLC grade water used throughout 
the analysis was obtained from the Merck Milli-Q water 
purification unit.
Instrument and apparatus
HPLC studies were carried out on Agilent series 
1260 infinity HPLC system (Open lab software) with 
a diode array detector (DAD) set at 213nm for UV 
detection. The HPLC column Kromasil C
18
 (250× 
4.6 mm, 5 μm) was used in the study. The Design of 
Expert (DOE) (7.0.0) modeling software (Stat-Ease 
Inc., Minneapolis, MN, USA) was employed for method 
optimization. Entire stress studies were carried out on 
Radley apparatus (Veego) having continuous stirring 
and temperature adjustable knob facility. pH meter used 
was Eutech instruments pH tutor, India. Other equipment 
required for this study were sonicator (Epei ultrasonic 
generator), analytical balance (Mettler Toledo), vortex 
meter (IKA Vortex) and a hot air oven (Yorco scientific).
Method development 
Preparation of drug solution
The stock solution was prepared by dissolved 
the drug equivalent to 1mg of trimethobenzamide in 
1mL of methanol and final volume was made up to 
10mL in a volumetric flask with methanol to achieve a 
concentration of 100 μg/mL. 
Preparation of buffer 
Ammonium formate buffer (1M) was prepared 
by taking 6.3gm of ammonium formate in 100mL of 
HPLC grade water in a volumetric flask. The solution 
was diluted 100 times to produce a 10mM strength. The 
buffer was filtered using 0.2 μm The buffer was filtered 
using a 0.2 μm Millipore filter, pH was measured and 
adjusted to the desired pH using formic acid. 
Ammonium acetate buffer (1M) was prepared by 
taking 7.7 gm of ammonium acetate in 100 mL of water 
(HPLC Grade water) in a volumetric flask. The solution 
was diluted 100 times to produce a 10 mM solution. 
The buffer was filtered using a 0.2 μm Millipore filter, 
pH was measured and adjusted to the desired pH using 
acetic acid. 
Optimization of the method
Initial HPLC runs with trimethobenzamide at a 
100 μg/mL concentration were performed using different 
buffers namely ammonium acetate and ammonium 
formate, different ratios of organic solvents (40%, 
47% and 54%) and different buffer strength of 10, 15 
and 20mM.
The initial trials were needed to optimize the 
final method. Total four factors including organic 
concentration, type of buffer, buffer strength and pH 
of the buffer were needed to optimize. Optimization 
of these parameters was varied over three level (high, 
mid and low) for four parameters including organic 
ratio from 40-54%, ammonium formate and ammonium 
acetate buffer system, 10-20 mM buffer strength, and 
buffer pH 5.8 and 6.8, respectively. 
Generation of stress samples Acid hydrolysis 
The analyte sample equivalent to 10 mg of 
trimethobenzamide was weighed, added into 3 mL of 
methanol and volume was made up to 10 mL with 5 N 
HCl solution. The degradation samples were kept in 
Radley apparatus with continuous stirring at 70 ºC for 
8h. After incubation, 1 mL of aliquots were withdrawn 
at 0, 1, 2, 4, 6 and 8 h. The samples were neutralized to 
pH 7 with NaOH solution, diluted and analyzed by the 
HPLC system.
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Base hydrolysis 
The analyte sample equivalent to 10mg of 
trimethobenzamide was weighed, added into 3 mL of 
methanol and volume was made up to 10 mL with 5N 
NaOH solution. The degradation samples were kept in 
Radley apparatus with continuous stirring at 70 ºC for 8 h. 
1 mL of aliquots were withdrawn at 0, 1, 2, 4, 6 and 8 h. 
The samples were neutralized to pH 7 with HCl solution, 
diluted and analyzed by the HPLC system.
Neutral hydrolysis
The analyte sample equivalent to 10mg of 
trimethobenzamide was weighed and dissolved in 10mL 
of water. These degradation samples were kept in Radley 
apparatus with continuous stirring at 70 ºC for 24 h. 1 mL 
of aliquots was withdrawn at 0, 6, 12, and 24 h. The 
samples were diluted with water and analyzed by the 
HPLC system.
Oxidative degradation
The analyte sample equivalent to 10mg of 
trimethobenzamide was weighed and dissolved in 




solution. These degradation samples 
were kept in dark area without disturbance at room 
temperature for 24 h. 1mL aliquots were withdrawn at 0, 
6, 12 and 24 h. These samples were diluted and analyzed 
by the HPLC system. 
Thermal degradation 
The analyte sample equivalent to 10 mg of 
trimethobenzamide was weighed on a petri dish and kept 
in a hot air oven at 70 ºC for 3 days. Sampling was done at 
multiple time points. Samples were dissolved in methanol, 
diluted 10 times and analyzed by the HPLC system. 
Photodegradation
An amount of 10mg trimethobenzamide was 
uniformly spread in a Petri dish and was exposed to 
direct sunlight for 24h. Sampling was done at multiple 
time points and analyzed by the HPLC system. 
Method validation
The final optimized chromatographic analytical 
method was validated as per the International 
Conference on Harmonization (ICH) Q2(R1) guidelines 
for system suitability, linearity, accuracy, precision, 
limit of detection, limit of quantitation and robustness 
(Araujo, 2009; Bhaumik et al., 2010; Bliesner, 2006; 
Gousuddin et al., 2017; ICH, 2005). The standard stock 
solution was prepared by dissolving the drug equivalent 
to 1mg of trimethobenzamide in 10 mL of methanol to a 
final concentration of 100 μg/mL. 
Linearity
Standard calibration curves were generated with 
seven different concentrations including the lower limit 
of quantification by making serial volume to volume 
dilution of stock solution over the range of 0.5-50 μg/
mL. Linear calibration curves were generated between 
peak area and drug concentration. The linearity was 
examined using linear regression, which was calculated 
by the least square regression method. 
Accuracy 
The accuracy of the developed analytical method 
was analyzed by injecting the analyte solution at three 
different level of concentrations (1.25 μg/mL, 25 μg/mL 
and 50 μg/mL) in triplicate. The percentage accuracy 
of trimethobenzamide at each level and each triplicate 
were calculated and the mean of percentage accuracy 
(n=3) and the relative standard deviation (RSD) 
was determined.
Precision 
The precision of the developed analytical method was 
determined by repeatability (intraday) and intermediate 
precision (interday) at three different levels (1.25 μg/mL, 
25 μg/mL and 50 μg/mL). Repeatability defines the use 
of the analytical procedure within a laboratory over a 
short period of time that was examined by assaying the 
samples during the same day. Intermediate precision was 
evaluated by comparing the assays on different days.
Limits of detection and quantitation 
Limits of detection (LOD) and limit of quantitation 
(LOQ) were determined from the signal-to-noise ratio. 
The detection limit was referring to as the lowest 
concentration level resulting in a peak area of three times 
the baseline noise. The quantitation limit was referring 
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to as the lowest concentration level that provided a peak 
area with a signal-to-noise ratio higher than ten.
System suitability 
The system suitability was determined by taking 
six replicates of the drug at the same concentration of 
30 μg/mL. The acceptance criteria were ±2% for the 
percent coefficient of variation (% CV) for the peak 
area, retention time of drug, theoretical plate count, 
and asymmetry. 
Robustness 
The robustness is one of the validation parameters 
that measures method capacity to remain unaffected 
by small, deliberate changes in chromatographic 
conditions. The robustness of the developed method was 
studied by testing the influence of small changes in the 
organic phase ratio (40-48%), flow rate (0.9 -1.1 mL/
min) and pH (5.3-6.3) of the mobile phase. 
RESULT AND DISCUSSION
Optimization of the method 
The percent organic concentration, pH and buffer 
strength was optimized considering the retention 
time, asymmetry, theoretical plates and peak area of 
the analyte. The experimental data for optimization 
of the method has been shown in Table I. In order 
to understand the effect of different factors on the 
chromatographic profile of trimethobenzamide, 3D 
plots were generated after processing all the data 
using the Design Expert software and the surface 
response graph has been shown in Figure 1. The figure 
shows the 3D plot as a function of percent organic 
concentration, pH and buffer strength. Considering 
the entire data set, the final optimized mobile phase 
which gave consistent and robust output consisted of a 
mixture of methanol and 14mM of ammonium formate 
buffer of pH 5.8 in a ratio of 44:56 (% v/v). The flow 
rate of the mobile phase was set at 1.0 mL/min. The 
detection of the analyte was carried out at 213 nm by 
PDA detector. The injection volume was 10 μL. Total 
chromatographic run time was 12 min. To confirm 
these optimum set of conditions, three replicate 
injections at 100 μg/mL of the analyte was analyzed 
to determine whether their observed retention time, 
area, asymmetry and theoretical plates were within 
the desired ranges. Representative chromatograms of 
blank and sample containing trimethobenzamide have 
been shown in Figure 2. 
















1 Formate 10 5.8 47 6.44 7510059 1.07 5815
2 Formate 20 5.8 47 5.93 6157731 1.08 5750
3 Formate 10 6.8 47 8.62 8322752 1.02 6845
4 Formate 20 6.8 47 6.30 5397765 1.11 5450
5 Formate 10 6.3 40 12.34 7587703 1.10 5553
6 Formate 20 6.3 40 10.13 5595228 1.08 5149
7 Formate 10 6.3 54 5.30 7665004 1.05 6059
(continuing)
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8 Formate 20 6.3 54 4.00 5734408 1.10 5414
9 Formate 15 5.8 40 11.88 7268780 1.09 5577
10 Formate 15 6.8 40 13.77 7323710 1.08 5310
11 Formate 15 5.8 54 5.08 7290879 1.13 6279
12 Formate 15 6.8 54 5.45 7365179 1.02 6085
13 Acetate 10 5.8 47 5.97 5249576 1.10 5116
14 Acetate 20 5.8 47 6.77 5742867 1.10 5732
15 Acetate 10 6.8 47 7.63 5167161 1.13 4941
16 Acetate 20 6.8 47 8.15 5903827 1.13 5951
17 Acetate 10 6.3 40 12.09 5229590 1.06 5041
18 Acetate 20 6.3 40 13.50 5560517 1.10 6368
19 Acetate 10 6.3 54 4.71 5456938 1.2 4959
20 Acetate 20 6.3 54 5.27 6159278 1.11 5444
21 Acetate 15 5.8 40 10.09 5325027 1.10 5557
22 Acetate 15 6.8 40 13.60 5340407 1.10 5517
23 Acetate 15 5.8 54 4.22 5443829 1.10 4919
24 Acetate 15 6.8 54 4.95 5572739 1.12 5076
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FIGURE 1 - Surface response graphs of A) Retention time as a function of pH, buffer strength and organic ratio B) Area as 
a function of pH, buffer strength and organic ratio C) Asymmetry as a function of pH, buffer strength and organic ratio D) 
Theoretical plates as a function of pH, buffer strength and organic ratio.
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FIGURE 2 - Representative chromatograms of A) Blank and 
B) Sample containing trimethobenzamide.
Stress degradation study
Acid hydrolysis 
The drug substance was exposed to 5N HCl and 
kept on Radley apparatus at 70 °C temperature for 8 h. It 
did not show any degradation in acid hydrolysis (Figure 
3A). The blank solution was also subjected to stress 
study in the same fashion as the drug solution which did 
not show any peak at the retention time of the drug.
Base hydrolysis 
The drug substance was exposed to 5 N NaOH and 
kept on Radley apparatus at 70 °C temperature for 8h. 
It showed 53% degradation in base hydrolysis with two 
degradation products which were labeled as DP-1 and 
DP-2. The retention time of two degradation products 
was about 3.01 and 8.20 min, respectively as shown in 
Figure 3B. The blank solution was also subjected to 
stress study in the same fashion as the drug solution 
which did not show any peak at the retention time of the 
drug or degradation products.
FIGURE 3 - Representative chromatograms of stress samples 
after degradation in A) Acidic B) Basic and C) Neutral 
conditions.
Neutral hydrolysis 
The drug substance exposed to water keeping on 
Radley apparatus at 70 °C temperature for 24 h. It showed 
no degradation in neutral hydrolysis as shown in Figure 
3C. The blank solution was also subjected to stress study 
in the same fashion as the drug solution which did not 
show any peak at the retention time of the drug.
Oxidative degradation





temperature for 24 h. Samples were withdrawn at 
different time intervals and injected into the HPLC 
system and chromatogram was recorded. There was 
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47% degradation with one degradation product having 
retention time 7.49 min as shown in Figure 4A. The blank 
solution was also subjected to stress study in the same 
fashion as the drug solution which did not show any peak 
at the retention time of the drug or degradation product.
FIGURE 4 - Representative chromatogram of stress samples 
after degradation in A) Oxidative B) Thermal and C) 
Photolytic conditions.
Thermal degradation 
The drug sample was exposed to 70 °C for 3 
days in a hot air oven and samples were withdrawn at 
different time intervals from 1 to 3 days. No degradation 
was found at the end of 3 days of exposure as shown 
in Figure 4B. The drug was thermostable at 70 °C. The 
blank solution was also subjected to stress study in the 
same fashion as the drug solution which did not show 
any peak at the retention time of the drug.
Photodegradation
The drug sample was exposed to direct sunlight 
for 24h and sample were withdrawn at different time 
intervals from 6 to 24h. Samples were injected into the 
HPLC system and chromatogram was recorded. No 
degradation was found at the end of 24h of exposure as 
shown in Figure 4C. Hence the drug can be considered 
as photostable. The blank solution was also subjected 
to stress study in the same fashion as the drug solution 
which did not show any peak at the retention time of the 
drug. Results of all the degradation studies have been 
summarized in Table II.
TABLE II - Summary of degradation study
Condition of 
degradation study
% of drug 
degraded
Retention time of 
degradant (min)
5N HCl, 8h No degradation -
5N NaOH, 8h 53%
3.01 and 8.20





















The Linearity of detector response of different 
concentration of drug was analyzed in the range from 
0.5 to 50 μg/mL (r2 =0.999). The regression equation 
obtained was Y=120775x, where Y is peak area and X 
is a concentration of the analyte (μg/mL). This equation 
was used to determine the amount of the analyte present 
in the stability samples. 
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 Accuracy
The average intraday accuracy at low (1.25 μg/
mL), medium (25 μg/mL) and high (50 μg/mL) level 
was found to be in the range of 94.22 to 101.18%. The 
average interday accuracy was found to be 94.03 to 
100.63%. The results for intra and interday accuracy 
study has been summarized in Table III.













1 1.26 0.01 0.65 101.18
2 1.25 0.01 0.94 100.08
Medium
(25μg/mL)
1 23.55 0.07 0.29 94.22
2 23.46 0.32 1.37 93.84
High
(50μg/mL)
1 50.20 0.19 0.39 100.39




1.26 0.01 0.94 100.63
Medium
(25μg/mL)
23.51 0.21 0.91 94.03
High
(50μg/mL)
50.19 0.19 0.37 100.38
Precision
Precision was calculated by studying three 
replicates of each of the concentration of low level, mid 
level and high level on different intervals on the same 
day (intraday) and on a different day (inter-day) and 
their mean, SD and %RSD was calculated. The RSD 
was found to in between 0.29 to 1.37% for intraday and 
0.37 to 0.94% for interday precision study. The low RSD 
value after repeated injections (below 2%) indicated that 
the developed method was precise. Table III is showing 
the results of intraday and interday precision study.
Limit of detection and limit of quantitation 
The limit of detection and limit of quantitation 
was determined by signal to noise ratio method. It was 
analyzed at the concentration level of 0.01 μg/mL. The 
LOD and LOQ obtained were 0.01 and 0.033 μg/mL, 
respectively.
System Suitability 
Six replicate injections of at the concentration 
level of 30 μg/mL of the analyte were injected into 
the HPLC system and different parameters including 
retention time, area, theoretical plate and asymmetry 
were determined for each individual peak. Mean, SD 
and %RSD were calculated for the six peaks. The RSD 
value was found to be 0.10% for retention time, 0.91% 
for peak area, 0.91% for asymmetry of the peak and 
0.48% for theoretical plate count. All the RSD values 
were less than 2%. The result of the system suitability 
study has been summarized in Table IV. 






1 5.35 3499964 0.91 4325
2 5.35 3534443 0.91 4279
3 5.36 3548169 0.92 4324
4 5.35 3588087 0.92 4293
5 5.36 3574268 0.9 4333
6 5.36 3524654 0.91 4315
Mean 5.35 3544931.00 0.91 4311.50
SD 0.005 32486.21 0.008 21.03
%RSD 0.10 0.91 0.91 0.48
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Robustness
Robustness was performed by changing the 
conditions like a minor change in pH, flow rate and 
organic ratio. The %RSD of area and asymmetry after 
minor flow rate change were 0.43 and 0.87, respectively. 
After changing the pH, the %RSD value were 1.41 and 
0.97 and after changing the organic ratio it was 1.01 
and 0.82, respectively. The analytical output was found 
to be unaffected due to a minor change in the tested 
chromatographic parameters. Results of the robustness 
study have been summarized in Table V.
CONCLUSION
A simple, robust and sensitive stability-
indicating HPLC assay method has been developed 
for quantification of trimethobenzamide in presence of 
their degradation products. The developed analytical 
method was accurate, precise and robust which is 
capable to separate and quantify all the degradants in 
stress samples. Degradation products were found only 
in basic hydrolysis and oxidative degradation. However, 
there was no degradation in acid, neutral, photo and 
thermal degradation. The developed method has been 
validated according to the ICH guideline. The developed 
method can be used for analysis of stability samples 
in routine quality control of trimethobenzamide in 
pharmaceutical industries. This research work thus can 
be considered to have a significant contribution to the 
field of pharmaceutical analysis.
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